Notably, TLR7/8 agonists have found utility as adjuvants in cancer immunotherapy due to their capacity to induce the production of IFN-Is, proinflammatory cytokines, chemokines, and the upregulation of costimulatory molecules through the MyD88 pathway [12]. Here, TLR7 is linked to cancer.